Abstract:Background Gut dysbiosis is postulated to participate in the pathogenesis of IgA nephropathy (IgAN). However, the key bacterial taxa closely associated with IgAN onset and treatment response have not been identified. Methods We recruited 127 patients with IgAN who were treatment naive and 127 matched healthy controls (HCs) who were randomly divided into discovery and validation cohorts to investigate the characteristics of their gut microbiota and establish a bacterial diagnosis model for IgAN. A separate cohort of 56 patients and HCs was investigated to assess crossregional validation. A further 40 patients with primary membranous nephropathy (MN) were enrolled to probe disease-specific validation. A subgroup of 77 patients was prospectively followed to further dissect the association between alterations in gut microbiota and treatment response after 6 months of immunosuppressive therapy. Fecal microbiota samples were collected from all participants and analyzed using 16S ribosomal RNA sequencing. Results Decreased α -diversity (Shannon, P =0.03), altered microbial composition (Adonis, P =0.0001), and a striking expansion of the taxonomic chain Proteobacteria – Gammaproteobacteria – Enterobacteriales – Enterobacteriaceae – Escherichia-Shigella (all P <0.001) were observed in patients with IgAN who were treatment naive, which reversed only in patients who achieved clinical remission after 6 months of immunosuppressive therapy. Importantly, seven operational taxa units, of which Escherichia-Shigella contributed the most, were determined to be the optimal bacterial classifier of IgAN (AUC=0.8635, 0.8551, 0.8026 in discovery, validation, and cross-regional validation sets, respectively), but did not effectively distinguish patients with IgAN versus those with MN (AUC=0.6183). Bacterial function prediction further verified enrichment of the shigellosis infection pathway in IgAN. Conclusion Gut dysbiosis, characterized by a striking expansion of genus Escherichia-Shigella , is a hallmark of patients with IgAN and may serve as a promising diagnostic biomarker and therapeutic target for IgAN. Further studies are warranted to investigate the potential contribution of Escherichia-Shigella in IgAN pathogenesis. Significance Statement Gut dysbiosis contributes to dysfunctional mucosal immunity, which may lead to production of nephrotoxic immune complexes specific to IgA nephropathy (IgAN). However, the key bacterial taxa closely associated with IgAN onset and treatment response have not been determined. We conducted a comprehensive observational study and found that, compared with healthy controls, patients with IgAN have a distinct gut microbial composition characterized by excessive expansion of the taxonomic chain Proteobacteria–Gammaproteobacteria–Enterobacteriales–Enterobacteriaceae–Escherichia-Shigella. Escherichia-Shigella contributed the most to the abundant taxonomic chain and performed best in the bacterial diagnosis model for distinguishing patients with IgAN from healthy controls. Strikingly, immunosuppressive therapy reversed the expansion of genus Escherichia-Shigella and increased bacterial diversity, but only in patients who achieved clinical remission. These results identify a crucial role of Escherichia-Shigella expansion in IgAN. Visual

Gut and respiratory microbiota landscapes in IgA nephropathy: a cross-sectional study

Potential Roles of Oral Microbiota in the Pathogenesis of Immunoglobin A Nephropathy

Systematic Microbiome Dysbiosis Is Associated with IgA Nephropathy

Gut Microbiome Characteristics in IgA Nephropathy: Qualitative and Quantitative Analysis from Observational Studies

Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy

Characteristics and function of the gut microbiota in patients with IgA nephropathy via metagenomic sequencing technology

Aberrant Gut Microbiome Contributes to Barrier Dysfunction, Inflammation, and Local Immune Responses in IgA Nephropathy

Associations of Genetic Variants Contributing to Gut Microbiota Composition in Immunoglobin A Nephropathy

The Effects of Specific Gut Microbiota and Metabolites on IgA Nephropathy—Based on Mendelian Randomization and Clinical Validation

Microbiome and metabolome analysis to clarify the interaction between the urine microbiota and serum metabolites in Chinese patients with immunoglobulin A nephropathy

Metagenomics-based systematic analysis reveals that gut microbiota Gd-IgA1-associated enzymes may play a key role in IgA nephropathy

Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies

[Changes of Gut Microflora in Newly Diagnosed IgA Nephropathy Patients and Its Correlation with Clinical Risk Factors].

Humoral immune responses primed by the alteration of gut microbiota were associated with galactose-deficient IgA1 production in IgA nephropathy

Gut Microbes in Immunoglobulin A Nephropathy and Their Potential Therapeutic Applications

Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis

Advancements in understanding the role of intestinal dysbacteriosis mediated mucosal immunity in IgA nephropathy

Functional networks of aging markers in the glomeruli of IgA nephropathy: a new therapeutic opportunity.

Is There a Role for Gut Microbiome Dysbiosis in IgA Nephropathy?

Reduced fecal short-chain fatty acids levels and the relationship with gut microbiota in IgA nephropathy

Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022